Literature DB >> 11772881

Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.

Giovanni Esposito1, Antonio Rapacciuolo, Sathyamangla V Naga Prasad, Hideyuki Takaoka, Steven A Thomas, Walter J Koch, Howard A Rockman.   

Abstract

BACKGROUND: A long-standing hypothesis has been that hypertrophy is compensatory and by normalizing wall stress acts to maintain normal cardiac function. Epidemiological data, however, have shown that cardiac hypertrophy is associated with increased mortality, thus casting doubt on the validity of this hypothesis. METHODS AND
RESULTS: To determine whether cardiac hypertrophy is necessary to preserve cardiac function, we used 2 genetically altered mouse models that have an attenuated hypertrophic response to 8 weeks of pressure overload. End-systolic wall stress (sigma(es)) obtained by sonomicrometry after 1 week of pressure overload showed complete normalization of sigma(es) in pressure-overloaded wild-type mice (287+/-39 versus sham, 254+/-34 g/cm2), whereas the blunted hypertrophic response in the transgenic mice was inadequate to normalize sigma(es) (415+/-81 g/cm2, P<0.05). Remarkably, despite inadequate normalization of sigma(es), cardiac function as measured by serial echocardiography showed little deterioration in either of the pressure-overloaded genetic models with blunted hypertrophy. In contrast, wild-type mice with similar pressure overload showed a significant increase in chamber dimensions and progressive deterioration in cardiac function. Analysis of downstream signaling pathways in the late stages of pressure overload suggests that phosphoinositide 3-kinase may play a pivotal role in the transition from hypertrophy to heart failure.
CONCLUSIONS: These data suggest that under conditions of pressure overload, the development of cardiac hypertrophy and normalization of wall stress may not be necessary to preserve cardiac function, as previously hypothesized.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772881     DOI: 10.1161/hc0102.101365

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  93 in total

Review 1.  Reverse remodeling in heart failure--mechanisms and therapeutic opportunities.

Authors:  Norimichi Koitabashi; David A Kass
Journal:  Nat Rev Cardiol       Date:  2011-12-06       Impact factor: 32.419

Review 2.  Protein kinase cascades in the regulation of cardiac hypertrophy.

Authors:  Gerald W Dorn; Thomas Force
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 3.  The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors.

Authors:  John Chambers
Journal:  Heart       Date:  2006-03       Impact factor: 5.994

4.  Divergence of hypertrophic growth and fetal gene profile: the influence of beta-blockers.

Authors:  X-J Du
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

5.  Effects of stretch and shortening on gene expression in intact myocardium.

Authors:  Charles R Haggart; Elizabeth G Ames; Jae K Lee; Jeffrey W Holmes
Journal:  Physiol Genomics       Date:  2013-12-03       Impact factor: 3.107

6.  Co-activation of nuclear factor-κB and myocardin/serum response factor conveys the hypertrophy signal of high insulin levels in cardiac myoblasts.

Authors:  Rosalinda Madonna; Yong-Jian Geng; Roberto Bolli; Gregg Rokosh; Peter Ferdinandy; Cam Patterson; Raffaele De Caterina
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

Review 7.  [Pathophysiology of heart failure].

Authors:  T Kempf; H Drexler; K C Wollert
Journal:  Internist (Berl)       Date:  2007-09       Impact factor: 0.743

8.  Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex.

Authors:  Hui-Hua Li; Vishram Kedar; Chunlian Zhang; Holly McDonough; Ranjana Arya; Da-Zhi Wang; Cam Patterson
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

9.  Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy.

Authors:  Catharina Ruppert; Katharina Deiss; Sebastian Herrmann; Marie Vidal; Mehmet Oezkur; Armin Gorski; Frank Weidemann; Martin J Lohse; Kristina Lorenz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

Review 10.  The rationale for cardiomyocyte resuscitation in myocardial salvage.

Authors:  Gerald W Dorn; Abhinav Diwan
Journal:  J Mol Med (Berl)       Date:  2008-06-19       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.